Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette‐Guérin
Authors:
- 23 February 2009
- journal article
- Published by Wiley in BJU International
- Vol. 103 (6) , 736-739
Abstract
OBJECTIVE: To evaluate the recurrence‐free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette‐Guérin (BCG) for high‐grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti‐inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms. PATIENTS AND METHODS: In all, 43 patients with carcinoma in situ (CIS) and/or high‐grade papillary bladder cancer were treated with intravesical BCG. Patients were stratified according to whether they took cardioprotective aspirin after treatment, and Kaplan‐Meier curves of RFS were compared by log‐rank analysis. Multivariable analysis was used for potentially confounding factors, including maintenance BCG, the presence of CIS, and smoking status. RESULTS: Of patients taking cardioprotective aspirin, the 5‐year RFS rate was 64.3%, compared with 26.9% for patients not taking aspirin, with a significantly higher RFS by univariable log rank analysis ( P = 0.03). Even after adjusting for the other factors by multivariable analysis, aspirin seems to affect recurrence (hazard ratio 0.179, P = 0.001). Maintenance BCG (hazard ratio 0.233, P = 0.02) and smoking history (hazard ratio 3.199, P = 0.05) also significantly affected recurrence. CONCLUSION: There was a significantly higher RFS rate in patients taking cardioprotective aspirin after intravesical BCG therapy for bladder cancer. The results of this study support the further investigation of aspirin and other NSAIDs as preventive agents in patients being treated for superficial bladder cancer.Keywords
This publication has 10 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control studyBMC Urology, 2007
- Age and Outcome of Superficial Bladder Cancer Treated with Bacille Calmette-Guérin TherapyUrology, 2007
- Long‐term outcome of hematuria home screening for bladder cancer in menCancer, 2006
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005
- COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancerSeminars in Oncology, 2004
- Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical IssuesJNCI: Journal of the National Cancer Institute, 2002
- MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, 2000
- Non-steroidal anti-inflammatory drugs and bladder cancer preventionBritish Journal of Cancer, 2000
- Bladder cancer: Natural history, tumor markers, and early detection strategiesSeminars in Surgical Oncology, 1997